---
schema_version: "secwatch.filing_event.v1"
accession: "0001601485-26-000041"
form_type: "8-K"
ticker: "ELTX"
cik: "0001601485"
company_name: "Elicio Therapeutics, Inc."
filed_at: "2026-05-11T20:09:10+00:00"
generated_at: "2026-05-11T22:28:04.103916+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Q1 net loss $11.8M ($0.65/sh); Phase 2 DFS readout mid-2026; cash runway into Q4

## Summary
- Q1 net loss $11.8M ($0.65/sh) vs $11.2M ($0.87/sh) YoY; R&D $6.8M, G&A $3.8M.
- Cash $14.9M at Mar 31; raised $13M via ATM in Q1-Q2; expected runway into Q4 2026.
- Phase 2 AMPLIFY-7P primary DFS analysis for ELI-002 7P in PDAC expected mid-2026; fewer events observed.
- Company remains blinded; after DFS readout, plans End-of-Phase 2 FDA meeting for Phase 3 design.

## SEC filing metadata
- accession: 0001601485-26-000041
- form_type: 8-K
- ticker: ELTX
- cik: 0001601485
- company_name: Elicio Therapeutics, Inc.
- filed_at: 2026-05-11T20:09:10+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601485/000160148526000041/0001601485-26-000041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601485/000160148526000041/eltx-20260511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601485-26-000041
- JSON: https://secwatch.observer/filing/0001601485-26-000041.json
- Plain text: https://secwatch.observer/filing/0001601485-26-000041.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.